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ABSTRACT
Introduction. Liver transplantation has become the most effective therapy for the treatment
of patients with end-stage liver disease. With new immunosuppressive agents the incidence of
acute rejection has been significantly reduced, but infection has become a serious problem.
Objective. Our objective was to correlate cytomegalovirus (CMV) positivity of antigen-
emia and polymerase chain reaction (PCR) with clinical manifestations and bacterial
infections among patients undergoing liver transplantation.
Methods. This prospective study included patients monitored for 6 months for early
detection of CMV infection. Sample collections were performed at the time of surgery and
weekly until the second month followed by fortnightly in the third month, and monthly in
the fourth to sixth month. CMV infection was defined by positive antigenemia (3 cells)
or 2 positive PCR tests associated or not with clinical symptoms. The methodology for the
diagnosis of bacterial infection was through biochemical tests and the automated VITEK/
bioMérieux (identification and antibiogram) using samples of urine and blood cultures.
Chi-square test was used for dicotomic variables with significant differences when P  .05.
Results. Sixteen patients (32%) had CMV infections, including 13 (81%) with concom-
itant infections. Thirty-four patients (68%) did not have CMV infections and 8 of these
(24%) had bacterial infection. There was a high correlation with bacterial infections
among CMV-positive patients.
Conclusion. Bacterial infections after liver transplantation were associated with CMV
infection.LIVER transplantation has become the most effectivetherapy for the treatment of patient with end-stage
liver disease. With new immunosuppressive agents, the
incidence of acute rejection episodes is significantly re-
duced, but infections have become a serious problem.1
Despite recent advances in prevention and treatment, cyto-
megalovirus (CMV) remains a major complication contrib-
uting to morbidity and mortality among transplant recipi-
ents.2,3 Most infections occur early (1–3 months) after
urgery, appearing to be associated with recipient or pre-
perative factors.
Bacterial infections mainly caused by gram-negative or-
anisms produce complications more frequentlly among
iver transplant recipients.4 The aim of this study was to
correlate antigenemia and polymerase chain reaction
(PCR) positivity for CMV with clinical manifestations and
bacterial infections among liver transplant recipients.
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1130METHODS
This prospective study included cases from February 2008 to
January 2010 who need the criteria older than 18 years, follow-up
greater than or equal to 30 days, serum immunoglobulin G (IgG)
positive for CMV pretransplantation, and signing of an informed
consent. Exclusion criteria were as follows: children, fulminant
hepatitis, retransplantation, and patients with serum (IgG) nega-
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CMV IN LIVER TRANSPLANTATION 1131tive for CMV pretransplantation. This study was approved by our
Institutional Ethics Committee (CEP no. 430/2003).
To detect CMV, antigenemia was examined by immunofluores-
cence in peripheral blood, using the methodology described by the
manufacturer (Kit CMV Brite Turbo, IQ Products, Netherlands).
DNA was obtained according to the method of Schmidt et al5 with
modifications. The PCR reaction to diagnoses the human gene
-globin was performed following the conditions described by De
ommaso et al6 with modifications. PCR used peripheral blood
leukocytes to detect CMV DNA, following the method described
by Nogueira et al7 with some modifications.
Patients were monitored for early detection of CMV infection
or 6 months. The sample collections were performed at the time of
urgery, weekly until the second month, fortnightly in the third
onth, and monthly from the fourth to the sixth month.
CMV infection was defined as positive antigenemia (3 cells) or
consecutive positive PCR results within an interval less than or
qual to 30 days associated with clinical symptoms. Clinical data
ere obtained through analysis of medical records and follow-up
isits. We considered clinical symptoms associated with CMV
nfection to be the following: fever, diarrhea, chest pain, flu-like
igns, and jaundice. Laboratory results associated with CMV
nfection were as follows: elevated liver profile (alkaline phospha-
ase, gamma glutamyl transferase, aspartate aminotransferase,
lanine aminotransferase, and total bilirubin), leukopenia, and
hrombocytopenia. To prevent infection by herpes virus in patients
ndergoing liver transplantation, acyclovir was prescribed for 6
eeks, concurrently with the standard immunosuppressive therapy
hat we have previously described.8
The cellular rejection episodes were treated with methylpred-
nisolone and CMV subjects received gancyclovir for 21 days with
ood clinical and laboratory responses.
The methodology for the diagnosis of bacterial infection was
iochemical tests and the automated VITEK/bioMérieux (identifica-
ion and antibiogram) using samples of urine and blood cultures.
RESULTS
During this period, 102 patients underwent liver transplan-
tation; 50 patients (49%) met the inclusion criteria. Thirty-
seven patients (74%) were males and 13 (26%) females,
with ages ranging from 22 to 70 years.
Only 4 patients were followed for less than 6 months due
to death 2 at 2 months, 1 at 4 months, and the other 1 at 5
Fig 1. Frequency of CMV infection observed in the period from
February 2008 to January 2010 associated or not with bacterial
infection (x2  12.61; P  .0004).months. Forty-six (92%) patients were for followed 6onths. During the study period, 40 patients showed good
ollow up.
Sixteen (32%) patients experienced CMV infections,
ith 13 (81%) showing concomitant bacterial infection.
hirty-four patients (68%) did not have CMV infection
ith 8 (24%) displaying bacterial infections (Fig 1).
In 6 patients, there was high positive antigenemia (5
ells), which coincided with the histological diagnosis of
cute cellular rejection. In 10 patients, the antigenemia was
ositive with low cellularity (up to 5 cells). None of these
atients has clinical symptoms related to active CMV
nfection, although 4 of them developed acute cellular
ejection episodes with symptoms of fever, sickness, myal-
ia, and jaundice.
Twenty-one patients had bacterial infections confirmed
y 23 positive hemocultures and 5 unocultures. In 3 patients
he bacterial infection was confirmed by hemoculture and
rocultures. Six displayed more than 1 microorganism. The
tiologic agents can be observed in Figure 2.
DISCUSSION
CMV infection is a major cause of morbidity and mortality
among liver transplant recipients. In this study, CMV
infection occurred among 16 (32%) transplant recipients,
consistent with the literature.9 A previous study in our liver
transplantation unit showed a 28% positivity for CMV
antigenemia.8,10
Infections developed during the first 3 moths, with peak
incidence between the the third and fourth month.11 In our
tudy we observed 21 patients with 28 bacterial infections,
onsistent with the literature.9
The common gram-negative bacilli after liver transplan-
tation cause major challenges for clinical treatment.4 Bac-
erial infections are the leading cause of death within the
rst year after liver transplantation. There were 2 recorded
ases of death in our study, namely at the second and sixth
onth after transplantation, respectively.
Approximately 80% of organ transplant recipients suffer
or more infections episode during the first year after
ransplantation.12 Our data corroborated the literature,
bserving 73% of infections.
An early diagnosis of CMV infection allows for immedi-
te treatment, prevents progression of clinical disease, and
Fig 2. Frequency of etiologic agents found in hemocultures
and urocultures according to CMV positivity.
1132 MILAN, SAMPAIO, GUARDIA ET ALreduces the risk of graft injury. Bacterial infections after
liver transplantation were associated with CMV infection.
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